Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Medications for substance use disorders.

Literature DB >> 23731419

Medications for substance use disorders.

Antoine B Douaihy¹, Thomas M Kelly, Carl Sullivan.

Abstract

In this article, the authors briefly review the pharmacotherapeutic agents that are currently available for the treatment of substance use disorders. Nicotine replacement therapies are most effective for tobacco cessation. Naltrexone, acamprosate, and disulfiram are effective for reducing alcohol use. The most effective pharmacotherapies for opiate use disorders are agonist therapies, including methadone and buprenorphine. The authors also examine recent advances in medication development for other substance use disorders such as stimulant addiction. The role of medication adherence and behavioral treatments and the integration of behavioral and pharmacotherapeutic interventions are also discussed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23731419 PMCID： PMC3767185 DOI： 10.1080/19371918.2013.759031

Source DB: PubMed Journal: Soc Work Public Health ISSN： 1937-190X

75 in total

Review 1. Individual behavioural counselling for smoking cessation.

Authors: T Lancaster; L F Stead
Journal: Cochrane Database Syst Rev Date: 2000

Review 2. Intramuscular extended-release naltrexone: current evidence.

Authors: David R Gastfriend
Journal: Ann N Y Acad Sci Date: 2011-01 Impact factor: 5.691

Review 3. Combating opiate dependence: a comparison among the available pharmacological options.

Authors: Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal: Expert Opin Pharmacother Date: 2004-04 Impact factor: 3.889

Review 4. The efficacy of disulfiram: a review of outcome studies.

Authors: J C Hughes; C C Cook
Journal: Addiction Date: 1997-04 Impact factor: 6.526

5. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.

Authors: Magí Farré; Anna Mas; Marta Torrens; Victor Moreno; Jordi Camí
Journal: Drug Alcohol Depend Date: 2002-02-01 Impact factor: 4.492

6. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal: JAMA Date: 2006-05-03 Impact factor: 56.272

Review 7. Immunotherapy for the treatment of drug abuse.

Authors: Thomas Kosten; S Michael Owens
Journal: Pharmacol Ther Date: 2005-10 Impact factor: 12.310

8. In alcohol-dependent drinkers, what does the presence of nicotine dependence tell us about psychiatric and addictive disorders comorbidity?

Authors: Yann Le Strat; Nicolas Ramoz; Philip Gorwood
Journal: Alcohol Alcohol Date: 2010-01-20 Impact factor: 2.826

9. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

Authors: R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam
Journal: JAMA Date: 1986-09-19 Impact factor: 56.272

Review 10. Clinical efficacy of bupropion in the management of smoking cessation.

Authors: Douglas Jorenby
Journal: Drugs Date: 2002 Impact factor: 9.546

11 in total

Review 1. Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment.

Authors: Rebecca J Houston; Nicolas J Schlienz
Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-09-23

2. Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue.

Authors: Lisa A Marsch; Kathleen M Carroll; Brian D Kiluk
Journal: J Subst Abuse Treat Date: 2013-09-14

3. Technology-based interventions and trainings to reduce the escalation and impact of alcohol problems.

Authors: Stella M Resko; Suzanne Brown; James J Lister; Steve Ondersma; Rebecca Cunningham; Maureen Walton
Journal: J Soc Work Pract Addict Date: 2017-04-19

4. Internet interventions for adult illicit substance users: a meta-analysis.

Authors: Nikolaos Boumparis; Eirini Karyotaki; Michael P Schaub; Pim Cuijpers; Heleen Riper
Journal: Addiction Date: 2017-04-25 Impact factor: 6.526

Review 5. Historical Review: Opiate Addiction and Opioid Receptors.

Authors: Shaocheng Wang
Journal: Cell Transplant Date: 2018-11-13 Impact factor: 4.064

Review 6. Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review.

Authors: Shao-Cheng Wang; Yuan-Chuan Chen; Chun-Hung Lee; Ching-Ming Cheng
Journal: Int J Mol Sci Date: 2019-09-02 Impact factor: 5.923

Review 7. Nanoparticle delivery systems for substance use disorder.

Authors: Vishal Kasina; Robert J Mownn; Raman Bahal; Gregory C Sartor
Journal: Neuropsychopharmacology Date: 2022-03-28 Impact factor: 8.294

8. Barriers to retention in substance use treatment: Validation of a new, theory-based scale.

Authors: Sarah E Zemore; Orrin D Ware; Paul A Gilbert; Miguel Pinedo
Journal: J Subst Abuse Treat Date: 2021-04-21

9. Post-operative Analgesia in Opioid Dependent Patients: Comparison of Intravenous Morphine and Sublingual Buprenorphine.

Authors: Shaabanali Alizadeh; Ghafar Ali Mahmoudi; Hassan Solhi; Bahman Sadeghi-Sedeh; Reza Behzadi; Amir Mohammad Kazemifar
Journal: Addict Health Date: 2015 Winter-Spring

10. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.

Authors: Sandra D Comer; Paolo Mannelli; Danesh Alam; Antoine Douaihy; Narinder Nangia; Sarah C Akerman; Abigail Zavod; Bernard L Silverman; Maria A Sullivan
Journal: Am J Addict Date: 2020-04-04